Antioxidative enzyme and glutathione S-transferase activities in diabetic rats exposed to long-term ASA treatment.
Low-dose acetylsalicylic acid (ASA) treatment is a standard therapeutic approach in diabetes mellitus for prevention of long-term vascular complications. The aim of the present work was to investigate the effect of long-term ASA administration in experimental diabetes on activities of some liver enzymes: glutathione peroxidase (GSHPx), catalase, glucose-6-phosphate dehydrogenase (G6PDH) and glutathione S-transferase (GST). Blood glucose, glycated hemoglobin, as well as plasma ALT and AST activities increased in rats with streptozotocin-induced experimental diabetes. The long-term hyperglycemia resulted in decreased activities of GSHPx (by 26%), catalase (by 34%), GST (by 38%) and G6PDH (by 27%) in diabetic animals. We did not observe increased accumulation of membrane lipid peroxidation products or altered levels of reduced glutathione in livers. The linear correlation between blood glucose and glycated hemoglobin in diabetic animals was distorted upon ASA treatment, which was likely due to a chemical competition between nonenzymatic protein glycosylation and protein acetylation. The long-term ASA administration partially reversed the decrease in GSHPx activity, but did not influence the activities of catalase and GST in diabetic rats. Otherwise, some decrease in these parameters was noted in ASA-treated nondiabetic animals. Increased ASA-induced G6PDH activity was recorded in both diabetic and nondiabetic rats. While both glycation due to diabetic hyperglycemia and ASA-mediated acetylation had very similar effects on the activities of all studied enzymes but G6PDH, we conclude that non-enzymatic modification by either glucose or ASA may be a common mechanism of the observed convergence.
Lapshina
E A
EA
Institute of Biochemistry, National Academy of Sciences of Belarus, BLK-50, Grodno, Belarus.
Sudnikovich
E Ju
EJ
Maksimchik
Ju Z
JZ
Zabrodskaya
S V
SV
Zavodnik
L B
LB
Kubyshin
V L
VL
Nocun
M
M
Kazmierczak
P
P
Dobaczewski
M
M
Watala
C
C
Zavodnik
I B
IB
D000818:Animals; D000975:Antioxidants / Q000378:metabolism*; D001241:Aspirin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001786:Blood Glucose / Q000032:analysis; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000188:drug therapy / Q000201:enzymology; D003925:Diabetic Angiopathies / Q000201:enzymology / Q000209:etiology / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D005982:Glutathione Transferase / Q000378:metabolism*; D006454:Hemoglobins / Q000032:analysis; D015227:Lipid Peroxidation / Q000187:drug effects; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008297:Male; D018384:Oxidative Stress / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar
D000975:Antioxidants; D001786:Blood Glucose; D006454:Hemoglobins; D010975:Platelet Aggregation Inhibitors; D005982:Glutathione Transferase; D001241:Aspirin